Biological and Biochemical Aspects of ML-236B (Compactin) and Monacolin K, Specific Competitive Inhibitors of 3-hydroxy-3-methylglutaryl Coenzyme A Reductase
In anticipation that plasma cholesterol levels may be lowered by inhibiting sterol synthesis in the liver, the major organ that supplies plasma cholesterol, studies aimed at identifying the specific inhibitors of cholesterol synthesis of microbial origin were started in my laboratory in 1971. Since then two novel compounds, ML-236B (compactin) and monacolin K, have been discovered and isolated as low-toxic, potent inhibitors of sterol synthesis from 14C acetate in a cell-free enzyme system of rat liver. This paper briefly reviews biological and biochemical data on these two compounds.
KeywordsCholesterol Synthesis Familial Hypercholesterolemia Plasma Cholesterol Level Sterol Synthesis Penicillium Citrinum
Unable to display preview. Download preview PDF.
- Doi O, End A (1978) Specific inhibition of desmosterol synthesis by ML-236B in mouse LM cells grown in suspension in a lipid-free medium. Japanese J Med Sci Biol 31: 225–233Google Scholar
- End A (1979a) Monacolin K, a new hypocholesterolemic agent produced by a Monascus species. J Antibiotics 32: 852–854Google Scholar
- End A (1979b) Monacolin K, a new hypocholesterolemic agent that specifically inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase. FEBS Letters, in pressGoogle Scholar
- Endo A, Kuroda M, Tsujit Y (1976a) ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum. J Antibiotics 29: 1346–1348Google Scholar
- Endo A, Tsujita Y, Kuroda M, Tanzaw K (1979) Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals. Biochim Biophys Acta, in pressGoogle Scholar
- Yamamoto A, Sudo H, End A (1979) Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis, in pressGoogle Scholar